What happened with BDX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Becton, Dickinson and Company (BD) supplies products used to deliver medicines, manage patient care and perform medical procedures. Its medical-delivery and care businesses generate most of its revenue: hospitals buy supplies such as syringes and catheters, alongside infusion pumps and medication-dispensing systems, while pharmaceutical companies buy prefillable syringes and injection systems for their drugs. BD sells disposable products through distributors and directly, and generally sells larger equipment directly to users.
BD also sells surgical and interventional devices to healthcare providers, and specimen-collection supplies, diagnostic instruments and reagents, and cell-analysis tools to laboratories and researchers. It plans to separate its Biosciences and Diagnostic Solutions businesses and combine them with Waters Corporation; completion remains subject to approvals and other conditions.
Demand depends partly on healthcare funding and reimbursement, which influence what customers buy and the prices they will pay. Manufacturing also relies on some sole-source materials and components; replacing suppliers can require regulatory approval. Most products need regulatory authorization before sale. The U.S. BD Alaris infusion-pump business remains subject to a consent decree, although an updated system has been cleared for sale and BD is remediating or replacing devices at customer sites.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BD’s results hinge on hospital consumables and procedure demand, while its planned combination of Biosciences and Diagnostic Solutions with Waters would materially change its exposure to research and diagnostic spending.
ICU Medical competes with BD for hospital purchases of infusion pumps, IV connectors, vascular-access devices, blood-flow monitoring and temperature-management products. Watch its pump business alongside infusion consumables: ICU Medical says pump sales may help it sell more higher-margin consumables.
Baxter International competes with BD for hospital spending on infusion systems, IV supplies, patient monitoring and surgical products. Its infusion systems and administration sets are the clearest products to watch against BD’s pumps and dedicated disposables.
Teleflex competes with BD for hospitals’ purchases of single-use devices that provide access to blood vessels and deliver infusions. Watch its product launches and cost-effectiveness in these consumables, rather than treating its wider range of procedures as a direct read-through to BD.
Boston Scientific competes with BD to supply hospital specialists with peripheral vascular intervention and urological devices. Its news in those two areas is more relevant to BD than results across its broader medical-device portfolio.
Medtronic competes with BD in consumables used to access blood vessels and devices used in peripheral vascular intervention.
West Pharmaceutical Services competes with BD to sell drugmakers systems that contain injectable medicines and let patients inject themselves. Watch West’s drug-containment and self-injection products for competition facing BD’s prefillable syringes and self-injection systems.
Stevanato Group competes with BD to supply pharmaceutical companies with containers and delivery systems for injectable drugs. Its EZ-fill ready-to-use injectable containers are a concrete product to watch against BD’s prefillable syringe business.
Solventum competes with BD for hospital purchases of infection-prevention products, IV-site care, surgical supplies and temperature-management products. Watch those lines within its MedSurg business, rather than its dental products or healthcare software.
Medline Inc.’s own-brand medical-surgical supplies compete with BD’s hospital consumables and surgical infection-prevention products. Its Medline Brand business is the relevant comparison; its separate supply-chain business also sells other manufacturers’ products.
Abbott Laboratories competes with BD in tests that detect infectious diseases and products used in peripheral vascular intervention.
Danaher’s diagnostic and life-science businesses compete with BD in molecular testing, laboratory systems and products used to analyze cells.
Thermo Fisher Scientific competes with BD for research and clinical laboratories’ purchases of diagnostic systems, cell-analysis products and reagents. Watch those purchases within its life-science and diagnostic businesses, not its broader pharmaceutical services.
AngioDynamics competes with BD in implanted access ports, drainage catheters and systems that remove plaque or blood clots from vessels. Its Auryon plaque-removal system and AngioVac and AlphaVac clot-removal systems are specific products to watch for competition in BD’s peripheral intervention business.
Merit Medical Systems competes with BD in devices for vascular access, peripheral intervention, drainage and oncology care. Its peripheral intervention products within the cardiovascular business are the most relevant line to watch, rather than its separate endoscopy business.
Bio-Rad competes with BD to sell cell-analysis and clinical laboratory instruments and reagents to laboratories. Watch its Life Science and Clinical Diagnostics businesses separately: the former includes cell-analysis tools, while the latter captures clinical diagnostic competition.
QIAGEN competes with BD to supply clinical laboratories with molecular testing instruments and the assays they consume. Its consumables revenue is the key line to watch, since consumables account for most of its sales rather than instruments.
Cytek Biosciences competes directly with BD to sell instruments that analyze cells using light—flow cytometers—and associated reagents to research and clinical laboratories and drugmakers. Watch its instrument base and recurring consumables sales, which Cytek seeks to grow from instruments already installed.
Boston Scientific Corp. earningsBSX
Boston Scientific's report will show demand for peripheral vascular and urological devices, areas where it competes with BD's interventional products.
Focus on Boston Scientific's peripheral vascular and urological businesses; growth elsewhere in its portfolio does not answer this question. Strength in those areas would show support for demand among hospital specialists, but also an active competitor for BD. Weakness could mean softer demand or a shift in competitive position. The takeaway is whether the markets BD serves have demand support and whether competition is intensifying.
West Pharmaceutical Services, Inc. earningsWST
West's report will show drugmaker demand for injectable-drug containers and self-injection systems, which compete with BD's prefillable syringes and self-injection products.
Focus on West's drug-containment and self-injection products, not every part of its business. Stronger sales in those products would show drugmakers are buying these systems, while also pointing to a stronger competitor for BD; weaker sales would mean less momentum for this West product line, not necessarily orders shifting to BD. The takeaway is demand for injectable-drug delivery systems and the rival's momentum.
QIAGEN N.V. earningsQGEN
QIAGEN's report will show clinical-lab demand for molecular-testing consumables, which compete with BD's molecular diagnostic products.
Focus on QIAGEN's consumables sales, not just instruments: laboratories need consumables to run tests. Steady consumables sales would show support for testing activity and purchasing in a market BD serves; weaker sales would point to less molecular-testing activity or fewer purchases. QIAGEN's results alone cannot show whether BD gained or lost share. The conclusion is whether demand for testing consumables in this market is holding up.
Medline Inc. earningsMDLN
Medline's report will show how hospitals are buying its own-brand medical supplies and surgical infection-prevention products, which compete with BD's offerings.
Focus on Medline's own-brand business, not its supply-chain sales of other manufacturers' products. Stronger own-brand sales would show hospitals are buying these supplies and that BD faces a more active rival; weaker sales would point to less momentum for that competitor, but would not prove BD won the orders. The takeaway is how active this category of hospital purchasing is and whether this rival is gaining ground.
Cytek Biosciences, Inc. earningsCTKB
Cytek's report will show lab and drugmaker demand for flow cytometers and related reagents, which compete directly with BD's cell-analysis products.
Read instrument sales alongside recurring consumables sales from installed systems. Growth in both would show customers buying flow cytometers and using the related reagents, with demand for both equipment and ongoing supplies. Weak instrument sales but growing consumables would show existing systems are still being used while new equipment purchases lag. The conclusion is whether cell-analysis demand supports both new instruments and follow-on supplies, and which is stronger.
Becton, Dickinson and Co. earningsThis company
BD's report will show whether sales to hospitals, laboratories and drugmakers are growing in a way that also lifts operating profit.
Read revenue growth alongside operating margins across BD's businesses. If revenue rises and margins hold or improve, sales of medical products, diagnostics and interventional devices are growing without the cost of serving customers eating away the added business. If revenue rises but margins fall, added sales are not yet producing better operating returns, leaving pricing or cost pressure unresolved.
ICU Medical Inc earningsICUI
ICU Medical's report will show hospital demand for infusion pumps and related supplies, which compete with BD's infusion systems and consumables.
Read infusion-pump sales alongside infusion-consumables sales. Growth in both would show hospitals buying equipment and continuing to order the supplies used with it. If pumps grow but consumables do not, new equipment sales are not yet bringing comparable supply sales; if both weaken, purchasing in this category is softer. The conclusion is whether hospital demand is broad and whether equipment sales lead to ongoing consumables purchases.
